FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959649067> ?p ?o ?g. }

• W2959649067 abstract "2616 Background: Acquired resistance to anti-EGFR MoAb therapy may be via EGFR-ErbB2 heterodimerization and pathway reactivation. Dual anti-EGFR treatment was recently found to be active in colon cancer. We performed a phase I trial of CET and LAP to determine the DLTs, MTD, and clinical activity of the combination. Methods: Pts received CET at 400mg/m2 then 250 mg/m2 weekly, combined with daily LAP in a 3+3 dose escalation trial. LAP dose levels (DL) were (1) 750mg, (2) 1000mg, and (3) 1250mg. Cycles lasted 3 weeks, toxicity was assessed through C2, and pts were restaged every 2 cycles. Baseline and post-C1 tumor biopsies were analyzed for phosphoprotein activation in 36 EGFR/ErbB2 pathway proteins. Germ-line pharmacogenetic (PGx) variations were correlated with efficacy and toxicity. Results: Between 10/2010 and 10/2012, 22 pts were enrolled - colon (8), lung (8), head and neck (4), and anal cancers (2) - and 59% had prior anti-EGFR therapy. 18 pts were evaluable for toxicity, and 18 for response. Mean treatment was 3.8 cycles (range 1 - 12); 3 patients are still on trial. One DLT occurred at DL1 (gr 3 rash) and DL2 (gr 3 diarrhea). No pt on DL3 experienced a DLT. No pt experienced a gr 4 toxicity; gr 3 toxicities anytime on therapy included rash (17%), diarrhea (6%), fatigue (6%), lymphopenia (6%), and hypomagnesemia (6%). Rash was experienced by 94% of pts (gr 1=50%, gr 2=28%, and gr 3=17%). Partial responses (PR) occurred in 4 pts (22%), stable disease (SD) in 8 (44%), and disease progression in 6 (33%), for a clinical benefit rate of 67%. Seven of 13 (54%) pts on prior EGFR therapy had SD or PR. Down-regulation of phosphorylated EGFR/ErbB2 pathway components correlated with response; distinct pathway components were up-regulated in non-responders, including PI3K, Jak/Stat, MAPK, and IGF. PGx variants in FcRII correlated with response (p=0.045); no variants correlated with toxicity. Conclusions: The RP2D is CET 250 mg/m2 weekly and LAP 1250mg daily. Treatment was well tolerated with few grade 3 toxicities and a significant 67% clinical benefit rate. Non-responders showed up-regulation of EGFR pathway components – components which are druggable, warranting further study. A trial in colorectal cancer is ongoing. Clinical trial information: NCT01184482." @default.
• W2959649067 created "2019-07-23" @default.
• W2959649067 creator A5000401547 @default.
• W2959649067 creator A5013113120 @default.
• W2959649067 creator A5013704556 @default.
• W2959649067 creator A5021453899 @default.
• W2959649067 creator A5024994699 @default.
• W2959649067 creator A5030650037 @default.
• W2959649067 creator A5045096676 @default.
• W2959649067 creator A5045107557 @default.
• W2959649067 creator A5059504028 @default.
• W2959649067 creator A5061373605 @default.
• W2959649067 creator A5081706282 @default.
• W2959649067 date "2013-05-20" @default.
• W2959649067 modified "2023-09-23" @default.
• W2959649067 title "Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors." @default.
• W2959649067 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.2616" @default.
• W2959649067 hasPublicationYear "2013" @default.
• W2959649067 type Work @default.
• W2959649067 sameAs 2959649067 @default.
• W2959649067 citedByCount "1" @default.
• W2959649067 countsByYear W29596490672021 @default.
• W2959649067 crossrefType "journal-article" @default.
• W2959649067 hasAuthorship W2959649067A5000401547 @default.
• W2959649067 hasAuthorship W2959649067A5013113120 @default.
• W2959649067 hasAuthorship W2959649067A5013704556 @default.
• W2959649067 hasAuthorship W2959649067A5021453899 @default.
• W2959649067 hasAuthorship W2959649067A5024994699 @default.
• W2959649067 hasAuthorship W2959649067A5030650037 @default.
• W2959649067 hasAuthorship W2959649067A5045096676 @default.
• W2959649067 hasAuthorship W2959649067A5045107557 @default.
• W2959649067 hasAuthorship W2959649067A5059504028 @default.
• W2959649067 hasAuthorship W2959649067A5061373605 @default.
• W2959649067 hasAuthorship W2959649067A5081706282 @default.
• W2959649067 hasConcept C121608353 @default.
• W2959649067 hasConcept C126322002 @default.
• W2959649067 hasConcept C143998085 @default.
• W2959649067 hasConcept C2777329042 @default.
• W2959649067 hasConcept C2779786085 @default.
• W2959649067 hasConcept C2779998722 @default.
• W2959649067 hasConcept C526805850 @default.
• W2959649067 hasConcept C530470458 @default.
• W2959649067 hasConcept C71924100 @default.
• W2959649067 hasConceptScore W2959649067C121608353 @default.
• W2959649067 hasConceptScore W2959649067C126322002 @default.
• W2959649067 hasConceptScore W2959649067C143998085 @default.
• W2959649067 hasConceptScore W2959649067C2777329042 @default.
• W2959649067 hasConceptScore W2959649067C2779786085 @default.
• W2959649067 hasConceptScore W2959649067C2779998722 @default.
• W2959649067 hasConceptScore W2959649067C526805850 @default.
• W2959649067 hasConceptScore W2959649067C530470458 @default.
• W2959649067 hasConceptScore W2959649067C71924100 @default.
• W2959649067 hasLocation W29596490671 @default.
• W2959649067 hasOpenAccess W2959649067 @default.
• W2959649067 hasPrimaryLocation W29596490671 @default.
• W2959649067 hasRelatedWork W1637035453 @default.
• W2959649067 hasRelatedWork W1980580409 @default.
• W2959649067 hasRelatedWork W2012934075 @default.
• W2959649067 hasRelatedWork W2036924356 @default.
• W2959649067 hasRelatedWork W2083199051 @default.
• W2959649067 hasRelatedWork W2130584549 @default.
• W2959649067 hasRelatedWork W2168730865 @default.
• W2959649067 hasRelatedWork W2240523956 @default.
• W2959649067 hasRelatedWork W2258698711 @default.
• W2959649067 hasRelatedWork W2282995421 @default.
• W2959649067 hasRelatedWork W2315896662 @default.
• W2959649067 hasRelatedWork W2317096894 @default.
• W2959649067 hasRelatedWork W2332684061 @default.
• W2959649067 hasRelatedWork W2343121555 @default.
• W2959649067 hasRelatedWork W2566896698 @default.
• W2959649067 hasRelatedWork W2590812426 @default.
• W2959649067 hasRelatedWork W2599447680 @default.
• W2959649067 hasRelatedWork W2907854036 @default.
• W2959649067 hasRelatedWork W2964827678 @default.
• W2959649067 hasRelatedWork W943998695 @default.
• W2959649067 isParatext "false" @default.
• W2959649067 isRetracted "false" @default.
• W2959649067 magId "2959649067" @default.
• W2959649067 workType "article" @default.